

Medication adherence to inhalation therapy and the risk of COPD exacerbations: a systematic review with meta-analysis

Delphine Vauterin ,¹ Frauke Van Vaerenbergh,¹ Maxim Grymonprez,¹ Anna Vanoverschelde ,^{1,2} Lies Lahousse^{1,2}

To cite: Vauterin D, Van Vaerenbergh F, Grymonprez M, et al. Medication adherence to inhalation therapy and the risk of COPD exacerbations: a systematic review with meta-analysis. *BMJ Open Respir Res* 2024;**11**:e001964. doi:10.1136/bmjresp-2023-001964

► Additional supplemental material is published online only. To view, please visit the journal online (<https://doi.org/10.1136/bmjresp-2023-001964>).

Received 18 July 2023
Accepted 3 September 2024



© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

¹Faculty of Pharmaceutical Sciences, Department of Bioanalysis, Ghent University, Ghent, Belgium

²Department of Epidemiology, Erasmus Medical Center, Rotterdam, Netherlands

Correspondence to

Professor Lies Lahousse;
lies.lahousse@ugent.be

ABSTRACT

Background Assessing medication adherence is crucial in chronic obstructive pulmonary disease (COPD) management to prevent exacerbations. However, it is unclear whether this association between adherence and exacerbations is influenced by the adherence assessment methods or thresholds used. Electronic healthcare databases are valuable to study exacerbations and adherence in real life. We aimed to systematically review the literature to identify adherence assessment methods and thresholds used in healthcare databases when investigating the association between medication adherence and COPD exacerbations and to meta-analyse the associated effect sizes.

Method MEDLINE, Web of Science and Embase were searched for peer-reviewed articles, written in English, published up to 10 October 2022 (PROSPERO: CRD42022363449). Two reviewers independently conducted screening for inclusion and performed data extraction. A qualitative approach described the adherence assessment methods and thresholds used. A quantitative approach (meta-analysis using random effects model) estimated the association between adherence and the risk of COPD exacerbations.

Results Eight studies were included in the systematic review of which five studies were included in the meta-analysis. The medication possession ratio (MPR) and the proportion of days covered (PDC) were the adherence assessment methods used and 0.80 was always used as threshold to differentiate good from poor adherence. Adherence and exacerbations were mostly measured over the same time period. Poor adherence (MPR or PDC<0.80) was significantly associated with a higher COPD exacerbation risk (OR 1.40, 95% CI 1.21 to 1.62, $I^2=85%$), regardless of the adherence assessment method used. Results were consistent when stratified by exacerbation severity. Poor adherence was also associated with a time-dependent risk of COPD exacerbations (incidence rate ratio 1.31, 95% CI 1.17 to 1.46).

Conclusion Our systematic review with meta-analysis demonstrated a 40% increased risk of COPD exacerbations in case of poor adherence to inhaler medication.

PROSPERO registration number CRD42022363449.

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Adherence to inhaler medication is crucial in chronic obstructive pulmonary disease (COPD) management to prevent exacerbations. The use of different methods to measure adherence and/or different adherence thresholds may result in different adherence values and/or proportions of adherent patients. It is unclear whether the association between adherence and COPD exacerbations can be demonstrated in healthcare databases and whether this observed association is influenced by the adherence assessment method or threshold used.

WHAT THIS STUDY ADDS

⇒ When meta-analysing studies assessing adherence to COPD medications (Anatomical Therapeutic Chemical classification code R03) and exacerbations in electronic healthcare databases, poor medication adherence (<0.80) was significantly associated with a higher probability of exacerbation occurrence (both moderate and severe exacerbations) and a higher frequency of severe exacerbations. The association between poor adherence and the risk of at least one COPD exacerbation was not impacted by the adherence assessment method used (medication possession ratio or proportion of days covered).

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ Electronic healthcare databases are a valuable resource to quickly identify poor adherent patients. These patients should be targeted for adherence interventions because our study demonstrated that, regardless of the adherence assessment methods used, poor adherence (<0.80) was associated with a 40% increased risk of COPD exacerbations.

INTRODUCTION

Exacerbations of chronic obstructive pulmonary disease (COPD) are defined in the 2024 Global Initiative for Chronic Obstructive Lung Disease (GOLD) report as episodes of acute respiratory symptom (dyspnoea and/or cough and sputum) worsening.¹ These

events represent a significant economic burden, affect disease morbidity and are linked to lung function deterioration.^{1–3} Poor adherence to pharmacological treatment has been associated with an increased risk of exacerbations and increased healthcare use.^{1,2} There is considerable variability in adherence rates calculated by different studies. Yet, medication adherence in patients with COPD is generally low, with adherence rates ranging from 7% to 78%.^{4,5} Adherence rates may vary depending on study type⁶ (clinical trials generally show higher rates than clinical practice), data source⁵ (self-reported estimates are generally higher than objective measures) and disease severity. In cases of advanced disease, the inhaled medication may be perceived as more necessary by the patient resulting in higher adherence values,⁷ although other studies have shown lower adherence in patients with multiple COPD treatments.⁸

Numerous methods to measure medication adherence exist.^{9–12} Consequently, it can be challenging to select the most appropriate assessment method.¹³ In addition, questions have been raised about the arbitrary cut-off point of 0.80 to categorise between good and poor adherence,¹⁴ and multiple cut-offs⁵ are currently used. The use of different methods to measure adherence and/or different adherence thresholds contributes to the large difference in adherence values and/or proportions of adherent patients between studies.^{5,15}

Electronic healthcare databases are a valuable resource to investigate exacerbations and medication adherence in real life, as they are easy to use, inexpensive and relevant to evaluate clinical outcomes.^{16,17} They have the advantage to investigate adherence and exacerbations without recall, reporting and/or response bias, which are important influencing factors in measuring adherence^{16,18} and exacerbations.¹⁹

To the best of our knowledge, there is no overview of the existing literature on the association between adherence and COPD exacerbations based on data from electronic healthcare databases and the adherence assessment methods and thresholds used in these studies. Moreover, it is unclear whether the association between adherence and COPD exacerbations can be demonstrated in healthcare databases and whether this observed association between adherence and exacerbations is influenced by the adherence assessment methods or thresholds used. Therefore, we aimed to systematically review literature on the association between adherence and COPD exacerbations to identify the most frequently used adherence assessment methods and thresholds based on data from electronic healthcare databases. Second, we aimed to summarise the corresponding effect sizes in a meta-analysis. We hypothesise that poor adherence is linked to an increased risk of exacerbations.

METHODS

This systematic review and meta-analysis is reported following the Preferred Reporting Items for Systematic

Reviews and Meta-Analyses (PRISMA) 2020 guidelines.²⁰ The protocol of this study was registered on PROSPERO²¹ (registration number: CRD42022363449).

Definition of adherence and exacerbation severity

While undertaking this review, medication adherence was defined as the extent to which a patient uses medication as recommended (taking into account the dosing regimen) over a specific period of time. This corresponds to the implementation part of the adherence process as defined by the Ascertaining Barriers for Compliance taxonomy for medication adherence.^{22,23} Definitions for COPD exacerbations and classification of severity were based on the GOLD 2023 report.¹ Severe exacerbations were defined as COPD-related hospitalisations, whereas moderate exacerbations were defined as events requiring treatment with oral corticosteroids and/or antibiotics in an outpatient setting.¹

Literature search and search strategy

Three databases (MEDLINE using the PubMed interface, Web of Science and Embase using the Embase.com interface) were extensively searched using search terms based on the following concepts: COPD, medication adherence, exacerbation and electronic healthcare database (summarised in online supplemental eTables 1–3). The search extended from inception of the database to 10 October 2022. Reference lists and citations of included studies were manually checked to identify other relevant articles.

Study inclusion criteria

Peer-reviewed studies, written in English, were eligible for inclusion in this systematic review. There was no restriction on the date of publication. Study populations were limited to patients with COPD. Only studies reporting the association between adherence to COPD maintenance therapy (Anatomical Therapeutic Chemical classification code R03) with a defined adherence threshold and the risk of COPD exacerbations were included. The study population identification, the adherence assessment and detection of exacerbations had to be based on an electronic healthcare database (eg, electronic healthcare records, medication prescription claims, pharmacy dispensing claims). Moreover, exacerbations had to be identified in the same time period or in a subsequent time period as the adherence assessment. Exacerbations needed to be stratified by exacerbation severity, comparable with the GOLD classification of exacerbation severity.¹ A complete overview of the inclusion and exclusion criteria can be found in online supplemental eTable 4.

Study selection

Two reviewers (DV and FVV) performed an independent screening of the title and abstract followed by

full-text evaluation, using Rayyan software.²⁴ Conflicts were resolved by a consensus meeting with a senior researcher (LL). Reviewers were blinded to each other's decisions. The Cohen's kappa coefficient²⁵ was calculated to determine the inter-rater reliability.

Quality assessment

The quality assessment was completed by the two reviewers (DV and FVV) independently, and discrepancies were discussed in a consensus meeting with the senior researcher (LL). Each included study was judged for their quality using the quality assessment tool 'QUAL-SYST' from the 'Standard Quality Assessment Criteria for Evaluating Primary Research Papers from a Variety of Fields' (chapter 3—online supplemental appendix).²⁶ Studies were included for meta-analysis if scoring at least 75% on the quality assessment.

Data extraction

A standardised data extraction table was developed to extract the study characteristics (study design, data collection method, factors for COPD diagnosis and recruitment setting), the baseline characteristics of the included population (sample size, age), the characteristics of the medication adherence assessment (medication assessed, measurement method, time period of assessment, threshold for differentiation between good and poor adherence) and the effect measures (exacerbation outcome, time period of assessment, time relation to adherence, statistics performed, results and adjustment factors/covariates) of the included studies. The table was pilot tested on three studies and refined by the two reviewers (DV and FVV). Subsequently, one reviewer (DV) performed the data extraction for all included studies, the other reviewer (FVV) checked the extracted data. Any disagreements were resolved by mutual agreement. When information or data were unclear or missing, the corresponding author of the included study was contacted.

Data analysis

A two-way approach was used for data synthesis: a qualitative descriptive approach to provide an overview of the extracted study characteristics with the medication adherence assessment methods and thresholds used in the included studies, and a quantitative approach (meta-analysis) to estimate the association between adherence and COPD exacerbations. A meta-analysis was performed on the risk of COPD exacerbations, separately for the occurrence of an exacerbation (risk of at least one exacerbation; exacerbator vs no exacerbator) and the time-dependent risk of COPD exacerbations (time to first severe exacerbation and/or frequency of exacerbations). A random effects model with the inverse-variance weighting method was used, and results were presented visually in a forest plot. Heterogeneity was tested using

the Cochran's Q-test, the between-study variance τ^2 (Paule-Mandel estimator)²⁷ and the I² statistic (which was considered to be low (<30%), moderate (30–60%) or high (>60%)). The effect sizes from each included study were reported as ORs for the risk of at least one exacerbation, and incidence rate ratios (IRR) for the time-dependent risk of COPD exacerbations. All effect sizes were presented with their 95% CI. The association between adherence and COPD exacerbations was investigated between the adherent group (reference) and poor adherent group (comparator). For studies with effect sizes expressed with the poor adherent group as reference, data conversions were performed. The risk of publication bias at the outcome level for the studies included in the meta-analyses was assessed by funnel plot asymmetry and by Egger's regression test. As a subgroup analysis, results were stratified by exacerbation severity. Moreover, the impact of different adherence assessment methods and adherence thresholds was investigated as a sensitivity analysis. Additionally, a sensitivity analysis was performed including studies that were initially excluded based on their quality score. A two-sided p value <0.05 was considered statistically significant. All analyses were performed with the meta package in R (R V.4.2.3 with RStudio V.2023.03.1 build 446).^{28,29}

RESULTS

Search results and quality assessment

After duplicates were removed, a total of 1365 unique studies were identified. After title and abstract screening, 66 studies were selected (Cohen's $\kappa=0.58$). After full-text assessment, six studies were included (Cohen's $\kappa=0.68$). In addition, two studies were included after identification in the reference and citation lists of the identified studies. Consequently, eight studies were included in the systematic review.

The assigned scores for the quality assessment ranged from 68% to 95% and are shown in online supplemental eTable 5. Due to a quality score of <75%, the studies by Fan *et al*,³⁰ Humenberger *et al*³¹ and Punekar *et al*³² were excluded from the meta-analysis. Consequently, five studies were included in the meta-analysis (figure 1).

Study characteristics

The general characteristics of the eight included studies are presented in table 1. Half of the included studies were conducted in North America,^{8 30 33 34} while other studies were performed in Europe^{31 32 35} or Asia.³⁶ The sample size varied from 357 to 45 937 included patients with COPD. The diagnosis of COPD was mainly based on an age criterion,^{8 30–33 35} associated with a diagnosis code (all included studies) and medication use (all included studies). Online supplemental eTable 6 provides an overview of the inclusion criteria of the different studies. Patients were selected based on only hospital data,³¹ only outpatient data^{8 32–34 36} or both.^{30 35}




Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.

Adherence assessment

Adherence assessment was based on the proportion of days covered (PDC, the number of days covered during a fixed time period),^{33 34 36} the medication possession ratio (MPR, the sum of days supplied during a patient-specific time period (eg, time between first and last prescriptions))^{8 31 32 34 35} or a variance of MPR/PDC (percentage of days supplied during a fixed time period)³⁰ (online supplemental eTable 7). All studies used a cut-off point of 0.80 to categorise between good and poor adherence. Davis *et al*³³ and Humenberger *et al*³¹ applied additional cut-off points to further divide the poor adherence group.

Exacerbation assessment

The majority of included studies assessed both moderate and severe exacerbations.^{8 30 32–34 36} In contrast, the study by Mueller *et al*³⁵ evaluated only moderate exacerbations and the study by Humenberger *et al*³¹ evaluated only severe exacerbations. An overview of the definitions of moderate and severe exacerbations used in each included study is available in online supplemental eTable 8. Adherence and exacerbation occurrence were measured over the same period of time in all included studies, except in the studies by Fan *et al*³⁰ (adherence in 90 days before occurrence of exacerbation) and Mueller *et al*³⁵ (exacerbations assessed in second half of 12-month adherence assessment period).

Association between adherence and COPD exacerbations

Results of all included studies are tabulated in online supplemental eTable 8. The reported effect sizes were adjusted for possible confounders (online supplemental eTable 6), including the exacerbation history (proxied by the number of preindex hospitalisations or emergency department visits for COPD exacerbations^{8 30 32 33 36} and/or the number of preindex prescriptions for short-acting bronchodilators,^{8 30 32 33 35 36} antibiotics^{8 30 33 36} and/or oral corticosteroids^{8 30 33 36}). In the study by Wurst *et al*,³⁴ no effect measures were available because only descriptive analyses were performed but the effect size (OR) could be calculated.

To investigate the impact of adherence on the risk of at least one exacerbation, four studies were included in a meta-analysis, while two studies were included in another meta-analysis to examine the impact of adherence on the frequency of exacerbations. No publication bias was suspected based on the visual inspection of the funnel plot (online supplemental eFigures 1 and 2) and Egger's regression tests, although the interpretability was limited due to inclusion of less than 10 studies.

Meta-analysis on risk of at least one COPD exacerbation

Poor adherence (MPR or PDC < 0.80) was significantly associated with a higher odds of exacerbation occurrence (pooled effect estimate: OR 1.40, 95% CI 1.21 to 1.62,

Table 1 General characteristics of the eight included studies

Author	Year	Country	Study design	Sample size	Age	Adherence assessment method	Threshold	Proportion of adherent patients
Chen et al ³⁶	2020	China	Retrospective Observational cohort	11 708	No age minimum, no mean/median/range presented	PDC	≥0.80 (sensitivity analysis for cut-off at 0.50)	10.8% in total; 36.3% in LABA and/or LAMA group, 26.4% in LABA/ICS group and 1.8% in oral mucolytic therapy group
Davis et al ³³	2017	USA	Retrospective Observational cohort	13 657	≥40 years, mean age of 67 years	PDC	Adherent: PDC≥0.80, mildly non-adherent: 0.50≤PDC<0.80, moderately non-adherent: 0.30≤PDC<0.50 and highly non-adherent: PDC<0.30	13.9% in LABA/ICS group
Fan et al ³⁰	2003	USA	Prospective Observational cohort	8033	≥45 years	% of days supplied during fixed time period of 90 days	>0.80	33% in ICS group
Humenberger et al ³¹	2018	Austria	Retrospective Observational cohort	357	>40 years, mean age of 66.5 years (SD 10.6)	MPR	Complete adherence: >0.80, partial adherence: 0.50–0.80 and low adherence: <0.50 together)	33.6% in total (LAMA, LABA, LABA/ICS, LABA/LAMA and LABA/LAMA/ICS users together)
Ismaila et al ⁸	2014	Canada	Retrospective Observational cohort	23 707	≥40 years, mean age of 73.2 years (SD 10.3)	MPR	≥0.80	61.1% in LAMA monotherapy group, 62.9% to LAMA in LABA/LAMA/ICS group and 35.4% to LABA/ICS in LABA/LAMA/ICS group

Continued



Table 1 Continued

Author	Year	Country	Study design	Sample size	Age	Adherence assessment method	Threshold	Proportion of adherent patients
Mueller <i>et al</i> ³⁵	2017	Germany	Retrospective Observational cohort	45 937	≥40 years, mean age of 71.4 years (SD 11.4)	MPR	≥0.80	30.0% in total; 38.0% in LABA group, 53.2% in LAMA group, 20.4% in ICS group and 26.8% in LABA/ICS group
Punekar <i>et al</i> ³²	2015	UK	Retrospective Observational cohort	17 529	≥40 years	MPR	≥0.80	34% in LABA group; 42% in LAMA group and 34% in LABA/ICS group
Wurst <i>et al</i> ³⁴	2014	USA	Retrospective Observational cohort	3268	≥40 to 65 years, mean age of 55.8 years (SD 5.4)	MPR and PDC	≥0.80	29.4% in LABA group and 37.1% in LAMA group

ICS, inhaled corticosteroids; LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonist; MPR, medication possession ratio; PDC, proportion of days covered.

$I^2=85\%$). The subgroup analysis based on exacerbation severity showed consistent results (figure 2). Poor adherence was associated with a significantly higher odds of moderate exacerbations (OR 1.56, 95% CI 1.19 to 2.04) and severe exacerbations (OR 1.32, 95% CI 1.21 to 1.43) (p value of 0.25 for test for subgroup differences). Results were consistent in a sensitivity analysis using the MPR or PDC for adherence assessment (online supplemental eFigure 3). Since all included studies used the cut-off point of 0.80 to categorise good and poor adherence, the impact of different adherence thresholds could not be assessed.

Meta-analysis on time-dependent risk of COPD exacerbations

Poor adherence (PDC<0.80) was also significantly associated with a higher frequency of severe COPD exacerbations (pooled estimated effect: IRR 1.31, 95% CI 1.17 to 1.46, online supplemental eFigure 4). There were insufficient data to perform meta-analysis for moderate exacerbations or for a sensitivity analysis investigating the influence of the adherence assessment method or adherence threshold.

Sensitivity analysis incorporating excluded studies

In a sensitivity analysis incorporating the study of Humenberger *et al*,³¹ poor adherence (MPR or PDC<0.80) remained significantly associated with a higher odds of exacerbation occurrence (pooled estimated effect: OR 1.28, 95% CI 1.05 to 1.56). However, in the subgroup analyses based on exacerbation severity, the pooled estimated effect was no longer significant for severe exacerbations (online supplemental eFigure 5a). The sensitivity analysis on the time-dependent risk of COPD exacerbations trended to a similar association between poor adherence (MPR or PDC<0.80) and the risk of COPD exacerbation (pooled estimated effect: exacerbation risk 1.16, 95% CI 0.94 to 1.42), although no longer significant (online supplemental eFigure 5b).

DISCUSSION

Our systematic review based on eight studies investigating the relationship between medication adherence and COPD exacerbations in electronic healthcare databases observed that adherence assessment was mainly based on the MPR, PDC or a variation of these methods. All included studies used a binary cut-off (0.80) to differentiate between good and poor adherence, although some studies added extra cut-offs to distinguish several groups of poor adherent patients.^{31 33} In our meta-analyses, we have demonstrated that poor adherence was associated with an increased risk of COPD exacerbations, both in occurrence and frequency.

The observed adherence assessment methods, MPR and PDC, were also the most prevalent methods in previous research in patients with asthma⁹ or in reviews focusing on oral dosages¹⁷ or on polypharmacy.³⁷ In




Figure 2 Subgroup meta-analysis based on exacerbation type for impact of adherence on exacerbation occurrence probability (random effects model). ADH, adherent group; ICS, inhaled corticosteroid; IV, inverse-variance; LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonist; PADH, poor adherent group.

contrast to the review of Asamoah-Boaheng *et al.*⁹ we did not consider the ratio of units of controller medication to the sum of units of controller medication and rescue medication (known as the asthma medication ratio) or the COPD treatment ratio as a measure of adherence. While it can be a valuable parameter in assessing disease control by treatment,³⁸ it is not designed to optimally measure adherence.

Approximately 30% of the patients with COPD showed good adherence in the included studies. This is in line with previous research, concluding that adherence rates in asthma and COPD varied widely depending on study type and disease severity.^{4 6 7} The results of our meta-analysis summarise the existing evidence of the association between adherence and COPD exacerbations in observational studies using electronic healthcare databases and validate previously published observations.^{39–41} Measuring adherence in observational studies is of particular value given that interventional studies (eg, randomised clinical trials) are characterised by restrictive inclusion and exclusion criteria and close follow-up of patients. This may result in adherence outcomes that are generally less reflective for real life.⁶

To compare the risk of COPD exacerbations among adherent versus poor adherent patients, potential confounders should be well balanced between the two groups. Therefore, we excluded studies with poor quality from the main analysis. A first important potential confounder is the level of disease severity (airflow limitation). If more severely ill patients are more adherent, the association between adherence and COPD exacerbations may be confounded by this factor as more severely ill patients are more at risk for exacerbations.³¹ This could explain why the sensitivity analysis, including studies previously excluded based on their quality score, was no longer significant. Second, previously published research showed that the exacerbation history is the strongest predictor of future exacerbations.^{1 42} All studies included

in the meta-analysis adjusted their effect sizes for exacerbation history, except for the study by Wurst *et al.*³⁴ (which included incident patients with COPD).

Based on [figure 2](#), it could be suggested that the effect of adherence to inhaled corticosteroids has a stronger influence on the risk of COPD exacerbations compared with long-acting bronchodilators. However, incident patients in the study by Wurst *et al.*³⁴ might have had a milder disease, while patients in the other studies have higher exacerbation risks related to more moderate or severe disease. Differences in the risk of COPD exacerbations between adherent patients and poor adherent patients may become more apparent in patients with moderate to severe disease, which may explain the observed difference between medication classes. To the best of our knowledge, no studies explored the association of medication adherence and the risk of COPD exacerbations in subgroups stratified by disease severity, and further research is therefore recommended.

The pooled estimated effect for moderate exacerbations was numerically higher than severe exacerbations (56% vs 32% higher odds, respectively), although no significant difference between subgroups ($p=0.25$ for test for subgroup differences) was observed. This means that the exacerbation severity did not modify the effect of poor adherence on the probability of COPD exacerbation occurrence. This small difference in pooled estimated effect may be explained by the higher prevalence of moderate exacerbations⁴³ and other risk factors influencing the need for hospitalisation, such as the socioeconomic status⁴⁴ and access to healthcare and/or health-seeking behaviour, which may vary between countries.⁴⁵

Strength and limitations

Our systematic review is, to the best of our knowledge, the first to provide an overview of adherence assessment



methods and thresholds used on data from electronic healthcare databases to investigate the association between adherence and COPD exacerbations and to summarise the associated effect sizes. However, a limitation of this systematic review, which may have resulted in studies with valid results being missed, was the exclusion of non-English language studies; although an extensive search strategy was used. Moreover, our inclusion criteria were based but not limited to validated definitions, although validation of algorithms to identify patients with COPD or COPD exacerbations in electronic healthcare databases exists.^{46–48} However, to the best of our knowledge, no validated algorithm is available that can be generally used in all electronic healthcare databases.

As adherence and exacerbations in all studies included in the meta-analysis assessed both parameters in the same time period, our results can only inform on an association but not on causation. Poor adherence is associated with an increased risk of COPD exacerbations.¹ On the other hand, adherence may increase after an exacerbation,^{49 50} or in contrast exacerbations may lower adherence.⁵¹ Therefore, a reverse causation between adherence and exacerbations cannot be excluded.

Since all included studies eligible for the meta-analysis on the impact of adherence on exacerbation occurrence used the cut-off point of 0.80 to distinguish between good and poor adherence, the impact of other adherence thresholds could not be assessed. Similar research in patients with asthma showed that adherence values ≥ 0.50 were associated with a reduced risk of asthma exacerbations.⁹

In addition, our results do not present the impact of the medication classes separately on the association between poor adherence and the risk of a COPD exacerbation, as we have pooled the effect sizes independently of the medication class studied. Furthermore, we excluded studies focused on short-acting bronchodilators only. This medication class can be used as add-on therapy for mild exacerbations, possibly interfering the association investigated in this systematic review.¹

Only the study of Humenberger *et al*³¹ used spirometry to inform COPD diagnosis and study inclusion. All other studies based COPD diagnosis on age, diagnosis codes registered and medication use. Electronic healthcare databases are characterised by some limitations such as the probability of coding errors, the inability to confirm if the patient actually has COPD or used the dispensed medication and the lack of information about the inhaler technique, spirometry results, patient-specific characteristics and laboratory values, such as blood eosinophil levels. Consequently, we were not able to confirm diagnosis of COPD nor appropriateness of medication. Furthermore, it should be noted there may be factors that influence the risk of COPD exacerbations that have not been taken into account when assessing the relationship between medication adherence and COPD exacerbations, such as smoking status.⁵² These limitations have to be taken into account.

Recommendations for clinical practice

As only observational studies were included in our research, our results must be interpreted with caution based on the Grading of Recommendations, Assessment, Development and Evaluations framework.⁵³ Nevertheless, some recommendations seem appropriate. Although the association between poor adherence and the risk of COPD exacerbations is generally known,¹ our research is, to the best of our knowledge, the first to summarise studies assessing this relationship in electronic healthcare databases. These resources are useful in clinical practice to objectively and quickly identify poor adherent patients.⁵⁴ It may be recommended to link an initial screening for non-adherent patients in an electronic database to an in-depth adherence assessment with assessment of the inhaler technique. Verified poor adherent patients with COPD could be targeted for adherence interventions (such as supportive telephone calls⁵⁵), as our study demonstrated that, regardless of the adherence assessment methods used, poor adherence (<0.80) was associated with a 40% increased risk of COPD exacerbations.

Research gaps

Adherence and COPD exacerbations were measured in the same time period for studies included in the meta-analysis. To further explore the impact of adherence on COPD exacerbations, research may investigate the long-term impact of adherence by assessing COPD exacerbations in a subsequent period of time.

The impact of other adherence thresholds other than 0.80 could not be assessed. Further research to validate the cut-off point of 0.80 in COPD is needed. Moreover, a second cut-off may be needed to assess the impact of overuse (MPR or PDC >1.20) on COPD exacerbations, which has been associated with an increased risk of severe COPD exacerbations as well.⁵⁶ In addition, further research should determine if these thresholds are independent of the exacerbation severity, the adherence assessment used and the medication class studied.

CONCLUSIONS

Our systematic review with meta-analysis demonstrated an increased risk of COPD exacerbations by poor adherence to inhaler medication, regardless of the adherence assessment method used. Results were consistent when stratified by exacerbation severity and highlight the importance of systematically screening adherence in patients with COPD.

Acknowledgements The authors thank Nele Pauwels, PhD, a methodologist from the Knowledge Center for Health Ghent, Ghent University, Belgium, for her advice concerning the methodology of this systematic review.

Contributors DV was responsible for the study concept, design and data analyses. FVV, MG and LL provided feedback to DV to optimise the methodology of this systematic review. DV and FW performed the study selection, the quality assessment and the data extraction. DV drafted the manuscript and FVV, MG, AV and LL critically reviewed the manuscript. DV had access to the data and takes

responsibility for the integrity of the conduct of the study and the accuracy of the data analysis as guarantor. All authors read and approved the final manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests Outside this manuscript, LL received a consulting fee paid to her institution from AstraZeneca, GSK and Sanofi and has given a lecture sponsored by Chiesi. Outside this manuscript, LL and MG have given lectures sponsored by IPSA vzw, a non-profit organisation facilitating lifelong learning for healthcare providers. Neither author has received any fees personally. LL is an unpaid member of European Respiratory Society and Belgian Respiratory Society, member of Faculty Board of Ghent University–Faculty of Pharmaceutical Sciences and faculty committees.

Patient consent for publication Not applicable.

Ethics approval Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Delphine Vauterin <http://orcid.org/0000-0002-8932-476X>

Anna Vanoverschelde <http://orcid.org/0000-0002-5902-917X>

REFERENCES

- Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for prevention, diagnosis and management of copd: 2024 report. 2024.
- Hogea S-P, Tudorache E, Fildan AP, *et al*. Risk factors of chronic obstructive pulmonary disease exacerbations. *Clin Respir J* 2020;14:183–97.
- Rennard SI, Farmer SG. Exacerbations and progression of disease in asthma and chronic obstructive pulmonary disease. *Proc Am Thorac Soc* 2004;1:88–92.
- Mäkelä MJ, Backer V, Hedegaard M, *et al*. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. *Respir Med* 2013;107:1481–90.
- Bhattarai B, Walpole R, Mey A, *et al*. Barriers and Strategies for Improving Medication Adherence Among People Living With COPD: A Systematic Review. *Respir Care* 2020;65:1738–50.
- Tashkin DP, Amin AN, Kerwin EM. Comparing Randomized Controlled Trials and Real-World Studies in Chronic Obstructive Pulmonary Disease Pharmacotherapy. *Int J Chron Obstruct Pulmon Dis* 2020;15:1225–43.
- George M. Adherence in Asthma and COPD: New Strategies for an Old Problem. *Respir Care* 2018;63:818–31.
- Ismaila A, Corriveau D, Vaillancourt J, *et al*. Impact of adherence to treatment with tiotropium and fluticasone propionate/salmeterol in chronic obstructive pulmonary diseases patients. *Curr Med Res Opin* 2014;30:1427–36.
- Asamoah-Boaheng M, Osei Bonsu K, Farrell J, *et al*. Measuring Medication Adherence in a Population-Based Asthma Administrative Pharmacy Database: A Systematic Review and Meta-Analysis. *Clin Epidemiol* 2021;13:981–1010.
- Jia X, Zhou S, Luo D, *et al*. Effect of pharmacist-led interventions on medication adherence and inhalation technique in adult patients with asthma or COPD: A systematic review and meta-analysis. *J Clin Pharm Ther* 2020;45:904–17.
- López-Campos JL, Quintana Gallego E, Carrasco Hernández L. Status of and strategies for improving adherence to COPD treatment. *Int J Chron Obstruct Pulmon Dis* 2019;14:1503–15.
- Vauterin D, Van Vaerenbergh F, Vanoverschelde A, *et al*. Methods to assess COPD medications adherence in healthcare databases: a systematic review. *Eur Respir Rev* 2023;32:230103.
- Karve S, Cleves MA, Helm M, *et al*. Prospective validation of eight different adherence measures for use with administrative claims data among patients with schizophrenia. *Value Health* 2009;12:989–95.
- Baumgartner PC, Haynes RB, Hersberger KE, *et al*. A Systematic Review of Medication Adherence Thresholds Dependent of Clinical Outcomes. *Front Pharmacol* 2018;9:1290.
- Malo S, Aguilar-Palacio I, Feja C, *et al*. Different approaches to the assessment of adherence and persistence with cardiovascular-disease preventive medications. *Curr Med Res Opin* 2017;33:1329–36.
- Anghel LA, Farcas AM, Oprean RN. An overview of the common methods used to measure treatment adherence. *Med Pharm Rep* 2019;92:117–22.
- Andrade SE, Kahler KH, Frech F, *et al*. Methods for evaluation of medication adherence and persistence using automated databases. *Pharmacoepidemiol Drug Saf* 2006;15:565–74; .
- Vitolins MZ, Rand CS, Rapp SR, *et al*. Measuring adherence to behavioral and medical interventions. *Cont Clin Trials* 2000;21:188S–94S.
- Sullivan PW, Ghushchyan VH, Campbell JD, *et al*. Measuring the cost of poor asthma control and exacerbations. *J Asthma* 2017;54:24–31.
- Page MJ, McKenzie JE, Bossuyt PM, *et al*. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:71.
- NIHR. International prospective register of systematic reviews (prospero) available from. Available: <https://www.crd.york.ac.uk/prospero/> [Accessed 9 May 2023].
- Vrijens B, De Geest S, Hughes DA, *et al*. A new taxonomy for describing and defining adherence to medications. *Br J Clin Pharmacol* 2012;73:691–705.
- Vrijens B, Dima AL, Van Ganse E, *et al*. What We Mean When We Talk About Adherence in Respiratory Medicine. *J Allergy Clin Immunol Pract* 2016;4:802–12.
- Ouzzani M, Hammady H, Fedorowicz Z, *et al*. Rayyan-a web and mobile app for systematic reviews. *Syst Rev* 2016;5:210.
- McHugh ML. Interrater reliability: the kappa statistic. *Biochem Med (Zagreb)* 2012;22:276–82.
- Kmet L, CookL, R L. The quality assessment tool ‘qualsyst’ from the ‘standard quality assessment criteria for evaluating primary research papers from a variety of fields.’ 2004. Available: https://www.ihe.ca/download/standard_quality_assessment_criteria_for_evaluating_primary_research_papers_from_a_variety_of_fields.pdf
- Veroniki AA, Jackson D, Viechtbauer W, *et al*. Methods to estimate the between-study variance and its uncertainty in meta-analysis. *Res Synth Methods* 2016;7:55–79.
- Balduzzi S, Rucker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. *Evid Based Ment Health* 2019;22:153–60.
- Tawfik GM, Dila KAS, Mohamed MYF, *et al*. A step by step guide for conducting a systematic review and meta-analysis with simulation data. *Trop Med Health* 2019;47:46.
- Fan VS, Bryson CL, Curtis JR, *et al*. Inhaled corticosteroids in chronic obstructive pulmonary disease and risk of death and hospitalization: time-dependent analysis. *Am J Respir Crit Care Med* 2003;168:1488–94.
- Humenberger M, Horner A, Labek A, *et al*. Adherence to inhaled therapy and its impact on chronic obstructive pulmonary disease (COPD). *BMC Pulm Med* 2018;18:163.
- Punekar YS, Landis SH, Wurst K, *et al*. Characteristics, disease burden and costs of COPD patients in the two years following initiation of long-acting bronchodilators in UK primary care. *Respir Res* 2015;16:141.
- Davis JR, Wu B, Kern DM, *et al*. Impact of Nonadherence to Inhaled Corticosteroid/LABA Therapy on COPD Exacerbation Rates and Healthcare Costs in a Commercially Insured US Population. *Am Health Drug Benefits* 2017;10:92–102.
- Wurst KE, St Laurent S, Mullerova H, *et al*. Characteristics of patients with COPD newly prescribed a long-acting bronchodilator: a retrospective cohort study. *Int J Chron Obstruct Pulmon Dis* 2014;9:1021–31.
- Mueller S, Wilke T, Bechtel B, *et al*. Non-persistence and non-adherence to long-acting COPD medication therapy: A retrospective cohort study based on a large German claims dataset. *Respir Med* 2017;122:1–11.
- Chen R, Gao Y, Wang H, *et al*. Association Between Adherence to Maintenance Medication in Patients with COPD and Acute Exacerbation Occurrence and Cost in China: A Retrospective Cohort Database Study. *Int J Chron Obstruct Pulmon Dis* 2020;15:963–71.



- 37 Pednekar PP, Ágh T, Malmenäs M, *et al.* Methods for Measuring Multiple Medication Adherence: A Systematic Review-Report of the ISPOR Medication Adherence and Persistence Special Interest Group. *V Health* 2019;22:139–56.
- 38 Stanford RH, Korrer S, Brekke L, *et al.* Validation and Assessment of the COPD Treatment Ratio as a Predictor of Severe Exacerbations. *Chronic Obstr Pulm Dis* 2020;7:38–48.
- 39 Vestbo J, Anderson JA, Calverley PMA, *et al.* Adherence to inhaled therapy, mortality and hospital admission in COPD. *Thorax* 2009;64:939–43.
- 40 Wu H, Zhang H, Li X, *et al.* Effects of medication adherence on disease activity in chronic obstructive pulmonary disease: a systematic review and meta-analysis. *Psychol Health Med* 2023;28:1656–70.
- 41 van Boven JFM, Chavannes NH, van der Molen T, *et al.* Clinical and economic impact of non-adherence in COPD: a systematic review. *Respir Med* 2014;108:103–13.
- 42 Hurst JR, Han MK, Singh B, *et al.* Prognostic risk factors for moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease: a systematic literature review. *Respir Res* 2022;23:213.
- 43 Whittaker H, Rubino A, Müllerová H, *et al.* Frequency and Severity of Exacerbations of COPD Associated with Future Risk of Exacerbations and Mortality: A UK Routine Health Care Data Study. *Int J Chron Obstruct Pulmon Dis* 2022;17:427–37.
- 44 Halpin DM, Miravittles M, Metzendorf N, *et al.* Impact and prevention of severe exacerbations of COPD: a review of the evidence. *Int J Chron Obstruct Pulmon Dis* 2017;12:2891–908.
- 45 Whittaker H, Van Ganse E, Dalon F, *et al.* Differences in severe exacerbations rates and healthcare utilisation in COPD populations in the UK and France. *BMJ Open Respir Res* 2022;9:e001150.
- 46 Rothnie KJ, Müllerová H, Hurst JR, *et al.* Validation of the Recording of Acute Exacerbations of COPD in UK Primary Care Electronic Healthcare Records. *PLoS One* 2016;11:e0151357.
- 47 Mapel DW, SamaSR, RoblinDW, *et al.* Validation of a US health insurance claims-based algorithm to identify acute exacerbations of chronic obstructive pulmonary disease. *Pharmacoepidemiol Drug Saf* 2020;29:394.
- 48 Gershon AS, Wang C, Guan J, *et al.* Identifying Individuals with Physician Diagnosed COPD in Health Administrative Databases. *COPD: Journal of Chronic Obstructive Pulmonary Disease* 2009;6:388–94.
- 49 Cvietusa PJ, Goodrich GK, Shoup JA, *et al.* Effect of an Asthma Exacerbation on Medication Adherence. *J Allergy Clin Immunol Pract* 2023;11:248–54.
- 50 Williams LK, Peterson EL, Wells K, *et al.* Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. *J Allergy Clin Immunol* 2011;128:1185–91.
- 51 Homętowska H, Świątoniowska-Lonc N, Klekowski J, *et al.* Treatment Adherence in Patients with Obstructive Pulmonary Diseases. *Int J Environ Res Public Health* 2022;19:11573.
- 52 Au DH, Bryson CL, Chien JW, *et al.* The effects of smoking cessation on the risk of chronic obstructive pulmonary disease exacerbations. *J Gen Intern Med* 2009;24:457–63.
- 53 Guyatt GH, Oxman AD, Vist GE, *et al.* GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;336:924–6.
- 54 Canfield SL, Zuckerman A, Anguiano RH, *et al.* Navigating the Wild West of Medication Adherence Reporting in Specialty Pharmacy. *J Manag Care Spec Pharm* 2019;25:1073–7.
- 55 Gregoriano C, Dieterle T, Breitenstein A-L, *et al.* Does a tailored intervention to promote adherence in patients with chronic lung disease affect exacerbations? A randomized controlled trial. *Respir Res* 2019;20:273.
- 56 Koehorst-Ter Huurne K, Groothuis-Oudshoorn CG, vanderValk PD, *et al.* Association between poor therapy adherence to inhaled corticosteroids and tiotropium and morbidity and mortality in patients with COPD. *Int J Chron Obstruct Pulmon Dis* 2018;13:1683–90.